Abstract 251P
Background
Uterine leiomyoma (UL) is the most common female pelvic benign tumor with recurrence rates of 16.7%-52.8%. We aimed to propose a prognostic index (PI) model for predicting the long-term (>5 years) risk of UL recurrence.
Methods
Women aged 18–44 years who initially underwent myomectomy for UL at one of the three study hospitals between April 2012 and October 2013 were enrolled. The data collected included patients’ demographics, leiomyomas’ characteristics, relapses, subsequent contraceptive methods, and postoperative gravidity and parity. A PI model was proposed based on the β-coefficients in the results of multivariate Cox regression analysis in prediction model group. The differences among the PI-based risk groups were tested by Kaplan–Meier analysis (using paired log-rank test) and univariate Cox regression analysis (using the Forward: LR) in prediction model, internal validation and external validation group.
Results
There were 725 patients included in this study. PI formula =1.5(if 3-5 leiomyomas)+2(if > 5 leiomyomas)+1(if residue)+1(if not submucosal)+1(if combined endometriosis). The PI value (0-5) was divided into low-risk group, intermediate-risk group, and high-risk group by cut-off values 1.25 and 3.75. In the prediction model group, the high-risk group had a significantly 4.55 times greater recurrence risk of UL than that in the low-risk group [cumulative recurrence rate (CR): 82.1% vs 29.5%, HR = 4.55, 95% CI; 2.821-7.339]; the intermediate-risk group had a significantly 2.81 times greater recurrence risk of UL than that in the low-risk group (CR: 62.3% vs 29.5%, HR = 2.81, 95% CI; 2.035-3.878). The differences between any two risk groups were also statistically significant (P < 0.05) in both internal and external validation groups.
Conclusions
The PI model was proved to be effective in distinguishing low-risk, intermediate-risk, and high-risk groups for long-term recurrence of UL after initial myomectomy in women aged 18-44 years, allowing it to be an objective tool aid in clinical decision making. In the future, prospective researches should be carried out to confirm the predictive ability of this PI model, and its practical value in clinical decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zheng Yu Li.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract